Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$67.37 USD

67.37
1,081,884

-1.02 (-1.49%)

Updated Sep 17, 2025 03:55 PM ET

After-Market: $67.49 +0.12 (0.18%) 6:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.

Zacks Equity Research

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

by Zacks Equity Research

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

Zacks Equity Research

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies in the first quarter.

Zacks Equity Research

What's in Store for Thermo Fisher (TMO) in Q1 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) is likely to have generated growth in the first quarter, driven by a favorable business mix and new launches.

Zacks Equity Research

3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Zacks Equity Research

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) first-quarter 2023 results are likely to witness impressive performance across its operating segments amid macroeconomic pressure.

Zacks Equity Research

HSIC or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. MMSI: Which Stock Is the Better Value Option?

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Zacks Equity Research

3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Invest in Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.

Zacks Equity Research

LabCorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.

Zacks Equity Research

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Zacks Equity Research

Best Growth Stocks to Buy for April 17th

by Zacks Equity Research

CROX, HSIC and IPAR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 17, 2023.

Zacks Equity Research

Henry Schein (HSIC) Stock Moves -0.17%: What You Should Know

by Zacks Equity Research

In the latest trading session, Henry Schein (HSIC) closed at $82.43, marking a -0.17% move from the previous day.

Zacks Equity Research

Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.

Zacks Equity Research

Merit Medical (MMSI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Zacks Equity Research

Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays

by Zacks Equity Research

Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.

Zacks Equity Research

Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable

by Zacks Equity Research

For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.

Zacks Equity Research

Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine

by Zacks Equity Research

Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.

Zacks Equity Research

Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Masimo's (MASI) slew of product launches.

Zacks Equity Research

Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Best Growth Stocks to Buy for April 13th

by Zacks Equity Research

CROX, HSIC and and GPK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 13, 2023.

Zacks Equity Research

BD's (BDX) New Launch to Result in Optimal IV Placement

by Zacks Equity Research

BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.